For the first few years of the GLP-1 era, getting one of these medications meant a weekly injection. That kept some people away, whether from a fear of needles or a sense that a shot meant something more serious than a pill. In 2026 that changed. Two daily pills are now approved for chronic weight management in the United States, and they work differently enough that the choice between them is not obvious.
The Wegovy pill
In December 2025 the FDA approved oral semaglutide 25 mg, sold as the Wegovy pill1, for adults with obesity or with overweight and at least one weight-related condition. It contains the same drug as the Wegovy and Ozempic injections. Because only a small fraction of a swallowed peptide survives the stomach, the pill dose is far higher than the weekly injection's 2.4 mg.
The approval rested mainly on OASIS 42, a 64-week trial of 307 adults without diabetes published in the New England Journal of Medicine. When everyone assigned to the pill was counted, including those who stopped, average weight loss was 13.6 percent, compared with 2.2 percent on placebo. Among those who kept taking it as directed, the average was 16.6 percent, and about one in three lost 20 percent or more of their body weight. The FDA also approved it to lower the risk of heart attack and stroke, based on the large SELECT trial of injectable semaglutide.
The catch is the routine. The pill must be swallowed first thing in the morning on an empty stomach with no more than 4 ounces of plain water. Then nothing, including coffee and other medications, for at least 30 minutes. Eating too soon substantially reduces how much drug is absorbed. Some people slot this into their morning without trouble. Others, especially those who take several other morning pills, find it harder than a weekly shot.
Orforglipron
On April 1, 2026, the FDA approved orforglipron3, sold by Eli Lilly as Foundayo, after a review the agency said took 50 days. It is a different kind of molecule. Instead of a peptide, it is a small chemical compound that activates the same GLP-1 receptor. That structure lets it survive digestion, so it can be taken at any time of day with or without food or water.
In the 72-week ATTAIN-1 trial of more than 3,000 adults with obesity or overweight, participants on the highest dose4 lost an average of 11.1 percent of body weight when everyone was counted, versus 2.1 percent on placebo. Among those who stayed on treatment, the figure was 12.4 percent.
How they compare
No trial has put the two pills side by side, and Novo Nordisk has publicly objected to claims that one outperforms the other. Reading across separate trials, with different populations and lengths, the Wegovy pill appears to produce somewhat more weight loss on average. Orforglipron trades a bit of potency for a far simpler routine. Both land below tirzepatide, sold as Zepbound, whose injection trials averaged about 21 percent.
Side effects look much like the injections for both pills. Nausea, constipation, diarrhea and vomiting are the most common, usually worst during dose increases. In OASIS 4, digestive side effects were reported by 74 percent of people on the pill and 42 percent on placebo. Both pills start at a low dose and step up over months to limit these effects.
Cost and access
Price has been the larger barrier for most people, and it is moving. Both companies now sell directly to cash-paying patients, with starting doses listed at $149 a month under pricing arrangements announced with the federal government. Higher maintenance doses cost more, and terms have changed several times in the past year, so check current pricing with the company or your pharmacy. Insurance coverage for obesity medications remains uneven, and many plans still exclude them.
What has not changed
A pill does not change the basic biology we described in our story on what happens when people stop a GLP-1. These are treatments for a chronic condition, and weight tends to return when they stop. There is no reason to expect a daily pill to behave differently from a weekly shot in that respect.
A pill may also be easier to forget. Missing a weekly injection is noticeable. Missing a daily tablet now and then may not be, and the effect of irregular dosing on long-term results is not well studied.
For someone who has avoided GLP-1 treatment because of needles, either pill is a genuine new option. For someone already doing well on an injection, there is little reason to switch unless cost, supply or preference changes. And for anyone starting out, the conversation with a clinician should cover the same ground as before, including protein intake, strength training to protect muscle, and a plan for the long term.
